Clinical Trial Update: Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of Vidutolimod (CMP-001) in combination with nivolumab for metastatic castration-resistant prostate cancer has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Vidutolimod
• nivolumab (nivolumab)

Snippet

Sponsor: Emory University | Conditions: Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 | Phase 2 | Status: SUSPENDED